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Dengue and 
Dengue Hemorrhagic Fever 
Information for Health Care Practitioners
Dengue is a mosquito-borne disease caused by any one of four closely related dengue viruses 
(DENV-1, -2, -3, and -4). Infection with one serotype of DENV provides immunity to that 
serotype for life, but provides no long-term immunity to other serotypes. Thus, a person can 
be infected as many as four times, once with each serotype. Dengue viruses are transmitted 
from person to person by Aedes mosquitoes (most often Aedes aegypti) in the domestic  
environment. Epidemics have occurred periodically in the Western Hemisphere for more 
than 200 years. In the past 30 years, dengue transmission and the frequency of dengue 
epidemics have increased greatly in most tropical countries in the American region. 
Dengue Hemorrhagic Fever  
and Dengue Shock Syndrome 
Some patients with dengue fever go on to develop  
dengue hemorrhagic fever (DHF), a severe and 
sometimes fatal form of the disease. Around the time 
the fever begins to subside (usually 3–7 days after 
symptom onset), the patient may develop warning 
signs of severe disease. Warning signs include severe 
abdominal pain, persistent vomiting, marked change 
in temperature (from fever to hypothermia),  
hemorrhagic manifestations, or change in mental 
status (irritability, confusion, or obtundation). The 
patient also may have early signs of shock, including 
restlessness, cold clammy skin, rapid weak pulse, and 
narrowing of the pulse pressure (systolic blood  
pressure − diastolic blood pressure). Patients with 
dengue fever should be told to return to the hospital 
if they develop any of these signs. 
DHF is currently defined by the following four  
World Health Organization (WHO) criteria:
•	 Fever or recent history of fever lasting 2–7 days.
•	 Any hemorrhagic manifestation.
•	 Thrombocytopenia (platelet count  
of <100,000/mm3).
•	 Evidence of increased vascular permeability. 
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 Clinical Diagnosis
Dengue 
Classic dengue fever, or “break bone fever,” is  
characterized by acute onset of high fever 3–14 days 
after the bite of an infected mosquito. Symptoms  
include frontal headache, retro-orbital pain, myalgias, 
arthralgias, hemorrhagic manifestations, rash, and 
low white blood cell count. The patient also may complain 
of anorexia and nausea. Acute symptoms, when present, 
usually last about 1 week, but weakness, malaise, and 
anorexia may persist for several weeks. A high proportion 
of dengue infections produce no symptoms or minimal 
symptoms, especially in children and those with no 
previous history of having a dengue infection. 
The main medical complications of classic dengue
fever are febrile seizures and dehydration. 
Treatment of dengue fever emphasizes 
•	 Relieving symptoms of pain.
•	 Controlling fever.
•	 Telling patients to avoid aspirin and other  
nonsteroidal, anti-inflammatory medications  
because they may increase the risk for hemorrhage.
•	 Reminding patients to drink more fluids,  
especially when they have a high fever.
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The most common hemorrhagic manifestations  
are mild and include a positive tourniquet test, skin 
hemorrhages (petechiae, hematomas), epistaxis  
(nose bleed), gingival bleeding (gum bleed), and 
microscopic hematuria. More serious types of 
hemorrhage include vaginal bleeding, hematemesis, 
melena, and intracranial bleeding. 
Evidence of plasma leakage due to increased vascular 
permeability consists of at least one of the following: 
•	 An elevated hematocrit ≥20% above the  
population mean hematocrit for age and sex. 
•	 A decline in hematocrit after volume-replacement 
treatment of ≥20% of the baseline hematocrit. 
•	 Presence of pleural effusion or ascites detected  
by radiography or other imaging method.
•	 Hypoproteinemia or hypoalbuminemia as  
determined by laboratory test.
WHO is currently reevaluating the clinical case 
definition for dengue fever and DHF. Studies from 
different countries have reported life-threatening 
complications from dengue in the absence of one or 
more of the current criteria for DHF. Despite the 
name, the critical feature that distinguishes DHF 
from dengue fever is not hemorrhaging, but rather 
plasma leakage resulting from increased vascular 
permeability. 
Dengue shock syndrome (DSS) is defined as any 
case that meets the four criteria for DHF and 
has evidence of circulatory failure manifested by 
What to Look for When You Evaluate Patients for DHF
EVALUATE the patient’s heart rate, capillary refill, skin color and temperature,  
peripheral pulse volume, pulse pressure, and blood pressure. A drop in systolic  
blood pressure is usually the last sign and appears only when the patient is in shock.
LOOK FOR evidence of bleeding on the skin and at other sites.
LOOK FOR evidence of increased capillary permeability 
(e.g., pleural effusions, ascites, hemoconcentration).
MEASURE and ask about urine output.
A female Aedes aegypti mosquito obtaining a  
blood-meal from a human host through her proboscis, 
which penetrates the host’s skin.
(1) rapid, weak pulse and narrow pulse pressure 
(≤20 mmHg [2.7 kPa]) or (2) hypotension for age, 
restlessness, and cold, clammy skin. Patients with 
dengue can rapidly progress into DSS, which, if not 
treated correctly, can lead to severe complications 
and death. 
Fatality rates among patients with DSS can be 10% 
or higher but, with early recognition and treatment, 
can be less than 1%. DHF and DSS can occur in 
both children and adults.
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How to Treat Dengue Fever
• Tell patients to drink plenty of fluids
 and get plenty of rest.
• Tell patients to take antipyretics to 
control their temperature. Children 
with dengue are at risk for febrile 
seizures during the febrile phase  
of illness.
• Warn patients to avoid aspirin  
and other nonsteroidal,  
anti-inflammatory medications  
because they increase the risk  
of hemorrhage.
• Monitor your patients’ hydration 
status during the febrile phase  
of illness. Educate patients and  
parents about the signs of  
dehydration and have them monitor 
their urine output.
• If patients cannot tolerate fluids 
orally, they may need IV fluids.  
Assess hemodynamic status  
frequently by checking the patient’s 
heart rate, capillary refill, pulse  
pressure, blood pressure, and  
urine output.
• Perform hemodynamic assessments, 
baseline hematocrit testing, and 
platelet counts.
• Continue to monitor your patients 
closely during defervescence.  
The critical phase of dengue  
begins with defervescence and  
lasts 24–48 hours.
 Clinical Management
Even for outpatients, stress the need to maintain  
adequate hydration. Monitoring for warning signs  
of severe dengue and initiating early appropriate 
treatment are key to preventing complications such 
as prolonged shock and metabolic acidosis. Successful 
management of DHF and DSS includes judicious 
and timely IV fluid replacement therapy with 
isotonic solutions and frequent reassessment of the 
patient’s hemodynamic status and vital signs during 
the critical phase. Health care providers should learn 
to recognize this disease at an early stage. To manage 
pain and fever, patients should be given acetaminophen. 
Aspirin and nonsteroidal, anti-inflammatory  
medications may aggravate the bleeding tendency  
associated with some dengue infections and, in  
children, can be associated with the development  
of Reyes syndrome. 
 Laboratory Diagnosis
Unequivocal diagnosis of dengue infection requires 
laboratory confirmation, either by isolating the virus 
or detecting dengue-specific antibodies. For virus 
isolation or detection of DENV RNA in serum 
specimens by serotype-specific, real-time reverse 
transcriptase polymerase chain reaction (RT-PCR), 
an acute-phase serum specimen should be collected 
within 5 days of symptom onset. If the virus  
cannot be isolated or detected from this sample, 
a convalescent-phase serum specimen is needed at 
least 6 days after the onset of symptoms to make a 
serologic diagnosis by testing for IgM antibodies to 
dengue with an IgM antibody-capture enzyme-linked 
immunosorbent assay (MAC-ELISA).
Acute-phase and convalescent-phase serum samples 
should be sent to the state health department or to 
the Centers for Disease Control and Prevention (CDC) 
for testing. Acute-phase samples for virus diagnosis 
may be stored on dry ice (-70°C) or, if delivery can be 
made within 1 week, stored unfrozen in a refrigerator 
(4°C). Convalescent-phase samples should be sent in  
a rigid container without ice, if next-day delivery is  
assured. Otherwise, they should be shipped on ice in an 
insulated container to avoid heat exposure during transit. 
Most tests for anti-dengue antibodies yield nonspecific 
results for flaviviruses, including West Nile and St. 
Louis encephalitis viruses. Because commercial kits 
may vary in sensitivity and specificity, test results 
may need to be confirmed by a reference laboratory.
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the Dominican Republic, El Salvador, Guatemala,  
Honduras, Mexico, Nicaragua, Panama, and Paraguay. 
Although its contact with humans and its density in 
urban areas are not as great as that of Aedes aegypti, 
this species also can transmit dengue viruses. 
As noted previously, the frequency of epidemic  
disease has increased significantly in the past 30 
years. Modern transportation makes it easy for 
travelers to visit virtually any location on the globe, 
including areas of the world where dengue is endemic. 
Although travel-associated dengue and limited 
outbreaks do occur in the continental United States, 
most dengue cases in U.S. citizens occur as a result 
of endemic transmission in some of the U.S.  
territories. CDC conducts laboratory-based, passive 
dengue surveillance in Puerto Rico in collaboration 
with the Puerto Rico Department of Health 
(PRDH). The PRDH Web site provides a weekly 
dengue surveillance report produced by CDC and 
PRDH at http://www.salud.gov.pr.
If a dengue-like illness is observed in a person in the 
continental United States who has recently traveled 
to a tropical area, acute and convalescent blood 
specimens, associated clinical information, and a 
brief travel history should be sent to the state public 
health laboratory with a request that the specimens 
be tested for dengue there or sent to CDC’s Dengue 
Branch in San Juan, Puerto Rico. Contact the CDC 
Dengue Branch for more information if needed. 
In Puerto Rico and the U.S. Virgin Islands, specimens 
and clinical information can be sent through the 
respective department of health or directly to the 
CDC Dengue Branch in San Juan.
For further information, contact
Dengue Branch, Centers for Disease Control and Prevention; 1324 Cañada Street;  
San Juan, Puerto Rico 00920-3860; Tel: (787) 706-2399; Fax: (787) 706-2496
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 Epidemiology 
A dengue epidemic requires the presence of 
•	 The vector mosquito (usually Aedes aegypti).
•	 The dengue virus.
•	 A large number of susceptible human hosts. 
Outbreaks may be explosive or progressive, depending 
on the density and efficiency by which the vector can 
be infected, the serotype and strain of the dengue virus, 
the number of susceptible (nonimmune) humans in the 
population, and the amount of vector-human contact.
 
Dengue should be considered as the possible etiology 
when leptospirosis, enterovirus, influenza, rubella, 
or measles are suspected in a dengue-receptive area 
(i.e., at a time and place where vector mosquito  
populations are abundant and active). In Puerto 
Rico and most countries of the Caribbean Basin,  
Aedes aegypti is abundant year-round. In the continental 
 United States, this species is seasonally abundant in 
Arizona, Louisiana, southern New Mexico, Texas, 
Florida, Alabama, Georgia, Mississippi, North  
and South Carolina, Oklahoma, Kentucky, and 
Tennessee. Given the competent vectors and 
susceptible population in the continental United 
States, isolated dengue outbreaks may occur (the last 
reported dengue outbreak was in Texas in 2005).
 
In 1985, a mosquito from Asia, Aedes albopictus, 
was found in the United States. This species is now 
found in most states in the southeastern part of the 
United States, as well as in Argentina, Barbados,  
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